Found: 6
Select item for more details and to access through your institution.
DFV890: a new oral NLRP3 inhibitor—tested in an early phase 2a randomised clinical trial in patients with COVID-19 pneumonia and impaired respiratory function.
- Published in:
- Infection, 2023, v. 51, n. 3, p. 641, doi. 10.1007/s15010-022-01904-w
- By:
- Publication type:
- Article
PASylation technology improves recombinant interferon-β1b solubility, stability, and biological activity.
- Published in:
- Applied Microbiology & Biotechnology, 2017, v. 101, n. 5, p. 1975, doi. 10.1007/s00253-016-7944-3
- By:
- Publication type:
- Article
A Phase 2a dose-escalation study of the safety, tolerability, pharmacokinetics and haemodynamic effects of BMS-986231 in hospitalized patients with heart failure with reduced ejection fraction.
- Published in:
- 2017
- By:
- Publication type:
- journal article
A Phase 2a dose-escalation study of the safety, tolerability, pharmacokinetics and haemodynamic effects of BMS-986231 in hospitalized patients with heart failure with reduced ejection fraction.
- Published in:
- European Journal of Heart Failure. Supplements, 2017, v. 19, n. 10, p. 1321, doi. 10.1002/ejhf.897
- By:
- Publication type:
- Article
N-terminal region of Saccharomyces cerevisiae eRF3 is essential for the functioning of the eRF1/eRF3 complex beyond translation termination.
- Published in:
- BMC Molecular Biology, 2006, v. 7, p. 1, doi. 10.1186/1471-2199-7-34
- By:
- Publication type:
- Article
A randomized, double-blind, placebo-controlled, multicentre study to assess haemodynamic effects of serelaxin in patients with acute heart failure.
- Published in:
- European Heart Journal, 2014, v. 35, n. 7, p. 431, doi. 10.1093/eurheartj/eht459
- By:
- Publication type:
- Article